Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 5mCRPC 1Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Specimen Handling 8Nivolumab 7pembrolizumab 4lenvatinib 3cabozantinib 3Ipilimumab 3Biopsy 3Axitinib 3vorolanib 2fludarabine 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2CTLA-4 Antigen 2toripalimab 1tivozanib 1sodium-iodide symporter 1sintilimab 1pazopanib 1fludarabine phosphate 1enzalutamide 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1atezolizumab 1abiraterone 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × enzalutamide × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡